In particular, the combination of lipocalin-1, dermcidin, lysozyme-C, and extracellular glycoprotein lacritin levels was proposed as a potential biomarker with a specificity of 77% and a sensitivity of 81%, and lacrimal gland dysfunction in AD was speculated [11]. This evidence concerns the gene LCN1 and Alzheimer disease.